Active Substance: Tranexamic acid.
Overview
Welcome to Dwaey, specifically on TAFIXYL 100mg/ml page.
This medicine contains an important and useful components, as it consists of
Tranexamic acidis available in the market in concentration
Tranexamic Acid
Mild to moderate renal impairment, irregular menstrual bleeding, previous history of thromboembolic disease, haematuria. Monitor closely in disseminated intravascular coagulation. Monitor LFT and eye examination regularly during long-term use. Discontinue if disturbance in colour vision occurs. Avoid IV inj rate >1 ml/minute due to risk of hypotension. Pregnancy, lactation.
Haemorrhage, Hereditary angioedema
Severe renal failure, active intravascular clotting, thromboembolic disease, colour vision disorders, subarachnoid bleeding.
>10% Headache (50.4%),Nasal and sinus symptoms (25.4%),Back pain (20.7%),Abdominal pain (19.8%),Musculoskeletal pain (11.2%) 1-10% Arthralgia (6.9%),Muscle cramps and spasms (5.8%),Migraine (6%),Anemia (5.6%),Fatigue (5.2%) Frequency Not Defined Visual abnormalities,Hypotension (with rapid injection),Nausea,Vomiting,Diarrhea
2
Tranexamic acid is an antifibrinolytic agent that competitively inhibits breakdown of fibrin clots. It blocks binding of plasminogen and plasmin to fibrin, thereby preventing haemostatic plug dissolution.
Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocytic leukaemia.
Information not available